JMP Securities Initiates Coverage On Mirum Pharmaceuticals with Market Outperform Rating, Announces Price Target of $70
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has initiated coverage on Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform rating and a price target of $70.
September 20, 2023 | 9:22 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mirum Pharmaceuticals has been given a Market Outperform rating by JMP Securities with a price target of $70.
The initiation of coverage by JMP Securities with a Market Outperform rating and a price target of $70 indicates a positive outlook for Mirum Pharmaceuticals. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100